

RealRate

PHARMACEUTICAL 2022

Forte Biosciences Inc. Rank 116 of 466







RealRate

PHARMACEUTICAL 2022

Forte Biosciences Inc. Rank 116 of 466

The relative strengths and weaknesses of Forte Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Forte Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Forte Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 221%, being 143% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	42,520
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,758
Liabilities, Non-Current	0
Other Assets	786
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-222
Other Revenues	0
Property and Equipment	0
Research and Development	13,853
Selling, General and Administrative Expense	7,633

Output Variable	Value in 1000 USD
Assets	43,306
Liabilities	1,758
Expenses	21,486
Revenues	0
Stockholders Equity	41,548
Net Income	-21,708
Comprehensive Net Income	-21,708
Economic Capital Ratio	221%

